ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Vaidya Sane Ayurved Laboratories Earnings Call: Key Takeaways

Madhavbaug reported FY26 revenue of ₹106.91cr (+18.89% YoY) and PAT of ₹8.99cr. The company is pivoting from wellness to higher-value disease reversal programs and expanding hospital capacity.

Why this was an Alfa AlertNot a filter event. Performance is in line with management's reported growth trajectory, not a material beat of prior guidance.
Highlights
Revenue growth18.89% YoY for FY26; targeting ~60% growth for FY27.
MarginsTargeting 15% EBITDA in FY27, scaling to 20% by FY28.
Demand visibilityIncreasing digital engagement; 1.5 lakh Instagram followers and growing patient inflow.
Management confidenceHigh; confident in 18-20% healthy growth and scaling to 30%.

Growth

FY26 Revenue grew 18.89% to ₹106.91cr. PAT increased to ₹8.99cr. H2 FY26 PAT grew 22.77% YoY to ₹4.15cr.

Outlook

Targeting FY27 revenue of ₹170-180cr. Medium-term FY28 target of ₹250-300cr with 20% EBITDA margins and 300 hospital beds.

Risks

High marketing spend (₹40-45cr targeted), operational challenges in non-medical franchise models, and potential dilution from preferential warrants.

Source

Earnings Call filed with NSE, NSE: MADHAVBAUG. Summary written with AI assistance from the document.

Read the document ↗

Vaidya Sane Ayurved Laboratories Ltd: key numbers

Share price
₹140.25
Market cap
₹147.4 Cr
Revenue (annual)
₹106.9 Cr
Net profit (annual)
₹8.99 Cr
P/E (TTM)
16.4×Sector 35.3×
Promoter holding
66.34%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Vaidya Sane Ayurved Laboratories Ltd

All →